This month’s cover molecule, Pfizer’s PF-07321332 (nirmatrelvir, API of Paxlovid) is an oral, reversible covalent SARS-CoV-2 main protease inhibitor, which has been submitted to the FDA by Pfizer for emergency approval for Covid treatment. Interim data showed Paxlovid reducing Covid hospitalization and death by 89%. It was nominated for this month’s [...]
1 minute read
Dec. 20, 2021
PF-07321332: an Oral, Reversible Covalent SARS-CoV-2 Main Protease Inhibitor
paxlovid
oral pan-coronavirus antiviral, rev. covalent Ph. III candidate for COVID-19 (300 mg BID) from SARS-CoV-1 inhibitor (WO2005113580) Science Pfizer Worldwide Research
Reviewer:
Loading...
